Almanac 2013: acute coronary syndromes

Open access

Summary

Unstable coronary artery plaque is the most common underlying cause of acute coronary syndromes (ACS) and can manifest as unstable angina, non-ST segment elevation infarction (NSTE-ACS), and ST elevation myocardial infarction (STEMI), but can also manifest as sudden cardiac arrest due to ischaemia induced tachyarrhythmias. ACS mortality has decreased significantly over the last few years, especially from the more extreme manifestations of ACS, STEMI, and cardiac arrest. This trend is likely to continue based on recent therapeutic progress which includes novel antiplatelet agents such as prasugrel, ticagrelor and cangrelor.

[1] Members WG, Roger VL, Go AS, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012;125: e2-220.

[2] Knight CJ, Timmis AD. Almanac 2011: acute coronary syndromes. The national society journals present selected research that has driven recent advances in clinical cardiology.

Heart 2011;97:1820-7.

[3] Yeh RW, Sidney S, Chandra M, et al. Population trends in the incidence and outcomes of acute myocardial infarction.

N Engl J Med 2010;362:2155-65.

[4] Nolan JP, Lyon RM, Sasson C, et al. Advances in the hospital management of patients following an out of hospital cardiac arrest. Heart 2012;98:1201-6.

[5] Fothergill RT, Watson LR, Chamberlain D, et al. Increases in survival from out-of-hospital cardiac arrest: a five year study. Resuscitation 2013;84:1089-92.

[6] Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 2012;307:1817-26.

[7] Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011;377:2193-204.

[8] Kimmelstiel C, Zhang P, Kapur NK, et al. Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2011;4:171-9.

[9] Meier P, Frohlich GM, Lansky AJ. Bleeding complications in percutaneous coronary interventions. Cardiology 2013;125:213-16.

[10] Mamas MA, Ratib K, Routledge H, et al. Influence of access site selection on PCI-related adverse events in patients with STEMI: meta-analysis of randomised controlled trials. Heart 2012;98:303-11.

[11] Meier P, Windecker S, Lansky AJ. Radial versus femoral access for primary percutaneous coronary intervention: is there a preferred route to the heart? Heart 2012;98:269-70.

[12] Baklanov DV, Kaltenbach LA, Marso SP, et al. The prevalence and outcomes of transradial percutaneous coronary intervention for ST-segment elevation myocardial infarction: analysis from the National Cardiovascular Data Registry (2007 to 2011). J Am Coll Cardiol 2013;61:420-6.

Seminars in Cardiovascular Medicine

The Journal of Lithuanian Heart Association

Journal Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 75 75 11
PDF Downloads 18 18 1